GT Biopharma, Inc. Restates Quarterly Financials: Critical Information for Investors

Overview

GT Biopharma, Inc. (“the Company”) has filed an amended quarterly report on Form 10-Q/A for the period ended September 30, 2025. This restatement follows a determination by the audit committee, in consultation with management, that previously issued interim financial statements should no longer be relied upon due to material errors. The restatement primarily addresses accounting misclassification regarding Greenshoe Rights connected to Series L Convertible Preferred Stock issued in May 2025.

Key Points in the Report

• Restatement Trigger: On March 1, 2026, the audit committee concluded that errors in the original quarterly report for Q3 2025 required restatement. The errors were identified during preparations for the year-end audit.
• Greenshoe Rights Accounting Error: The Company failed to classify Greenshoe Rights as a liability in compliance with ASC 480 (GAAP), leading to incorrect balance sheet and income statement entries. These rights should have been marked to market at every reporting date.
• Material Adjustments: The restatement impacts the balance sheet, statement of operations, and cash flows. Notably, the fair value of the Greenshoe Rights liability was adjusted by \$11,413,000 for the nine months ended September 30, 2025, which is a substantial figure for investors to note.
• Internal Controls: The Company determined that its disclosure controls and procedures as of September 30, 2025, were ineffective due to these errors.
• No Principal Executive Office: Effective July 1, 2024, GT Biopharma became a fully remote company and does not maintain a principal executive office.
• Current Share Structure: As of November 6, 2025, there were 10,636,135 shares of common stock outstanding.
• Filing Status: The Company is a non-accelerated filer, a smaller reporting company, and is not an emerging growth company.
• Stock Listing: Common Stock (\$0.001 par value per share) trades on Nasdaq Capital Market under the symbol GTBP.
• No Revenues: The Company reported no revenues for the three and nine months ended September 30, 2025.
• Net Income (Loss):
  • Q3 2025: \$4,097,000 net income attributable to common stockholders.
  • YTD Q3 2025: (\$26,933,000) net loss.
• Per Share Results:
  • Q3 2025: Net Income per share (basic & diluted): \$1.04.
  • YTD Q3 2025: Net Loss per share (basic & diluted): (\$8.90).
• Balance Sheet:
  • Total assets as of September 30, 2025: \$4,321,000.
  • Total liabilities and stockholders’ equity as of September 30, 2025: \$4,321,000.
  • Common stock value: \$6,000 (issued and outstanding: 2,234,328 shares as of September 30, 2025).
  • Additional paid-in capital: \$721,095,000.
• Preferred Stock: Series L Convertible Preferred Stock was the source of the accounting error. No value was assigned for preferred stock as of September 30, 2025, reflecting the impact of the restatement.
• Dividends and Deemed Dividends:
  • Dividends on preferred stock for Q3 2025: \$144,000.
  • Deemed dividend for Q3 2025: \$4,058,000.
• Restatement Details: The Company is restating condensed financial statements and related information for Q3 2025 to correct the Greenshoe Rights misclassification. Reference to “Note 2 – Restatement of Quarterly Financial Statements (Unaudited)” is made for further details.
• Filing Compliance: The Company confirmed it has filed all required reports and submitted all Interactive Data Files as required by Regulation S-T.
• Not a Shell Company: Explicitly stated.

Shareholder Considerations & Price Sensitivity

• Restatement Impact: The restatement of previously filed financials is a material event, especially given the significant \$11.4 million adjustment related to Greenshoe Rights. This could affect investor confidence and potentially impact GTBP’s share price.
• Internal Control Weakness: The Company’s admission of ineffective disclosure controls as of September 30, 2025, may raise concerns about the reliability of future financial statements and the robustness of internal processes.
• Preferred Stock & Liability Classification: The error in not recognizing Greenshoe Rights as a liability under ASC 480 may signal misjudgments in financial reporting, which is a key risk factor for shareholders and could be price sensitive.
• Unusual Share Structure: The number of shares outstanding versus the common stock value and additional paid-in capital may prompt questions on capital structure, dilution, and valuation.
• Operational Risks: The Company has no principal executive office and is fully remote. While this may be cost-effective, it could introduce risks regarding oversight and operational effectiveness.
• No Revenue and Large Losses: The Company reported no revenues and a substantial year-to-date net loss, which are negative signals for value investors.
• Dividends & Deemed Dividends: Deemed dividends of \$4 million in Q3 may impact earnings per share and shareholder returns.

Summary Table

Investor Takeaways

• Material Accounting Restatement: The correction of Greenshoe Rights classification is highly material and may lead to volatility in GTBP’s share price.
• Internal Control Concerns: Investors should closely monitor future filings and any remediation steps for the Company’s internal controls.
• Financial Health: The absence of revenue and large losses is a significant concern for both current and prospective shareholders.
• Monitor for Further Developments: The restatement and control weaknesses may attract regulatory scrutiny or additional changes to financial statements.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence before making investment decisions. The restatement described above may affect GT Biopharma, Inc.’s share price, but future price movements are subject to various factors and uncertainties. The information presented is based on the restated 10-Q/A filing for the period ended September 30, 2025, and may be updated or revised in subsequent filings.

View GT Biopharma, Inc. Historical chart here